Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
ZERBAXA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
ZERBAXA
Date registered
Evaluation commenced
Decision date
Approval time
169 working days (255)
Active ingredients
ceftolozane sulfate; tazobactam sodium
Registration type
EOI
Indication
ZERBAXA (powder for injection) is now also indicated for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP) infections in adults suspected or proven to be caused by designated susceptible microorganisms.